(Adnkronos) - Sindrome ipereosinofila: il Ready to HES 2024, ospitato a Torino, si pone l’obiettivo ambizioso di differenziare e inquadrare correttamente la malattia, offrendo un modello di approccio metodologico per la raccolta di esperienze cliniche a livello nazionale. "Oggi abbiamo a disposizione un anticorpo che agisce nei confronti dell'interleuchina 5, che è un po' il fattore che determina la crescita degli eosinofili – afferma la dott.ssa Cristina Papayannidis, Dirigente medico dell’IRCCS A.O.U. di Bologna - Istituto di Ematologia Seràgnoli – Questo anticorpo ha la capacità di modificare e migliorare i sintomi che questi pazienti possono presentare, di conseguenza ne migliora la qualità di vita".
Category
🗞
NewsTranscript
00:00 [MUSIC]
00:05 Today we are talking about hyperosinophilic syndrome.
00:07 And in this context, the hematologist also plays a key role.
00:13 In which steps?
00:14 So, first of all, from a diagnostic point of view,
00:17 the role of the hematologist is to first exclude those that are
00:20 middle clonal pathologies caused by the presence of rearrangement or
00:26 genomic alterations that determine an abnormal proliferation of the osinophiles,
00:31 which are, we know, a subgroup of white blood cells circulating in the peripheral blood.
00:36 To do this, the hematologist undergoes diagnostic exams
00:40 through advanced molecular biology technologies,
00:43 which allow us to identify or less such alterations.
00:48 It is a subgroup, however,
00:50 very limited in percentage, responsible for the causes of hyperosinophilia.
00:55 But it is good to exclude them, precisely because where they are present,
00:59 they start a targeted therapeutic program characterized by an approach
01:04 with inhibitors that are able to completely remove
01:09 the vast majority of patients, even for very long periods of time.
01:14 When this type of pathology is excluded,
01:18 therefore this type of problem, all other specialists,
01:22 sooner or later, already have or are already carrying out their therapeutic hitter
01:27 to try to understand what is the cause related to osinophilia.
01:31 Where there is no cause found, and therefore where all secondary factors
01:35 that can induce this type of alteration are excluded,
01:38 then we will talk about idiopathic forms.
01:41 And therefore idiopathic forms in front of which we have today,
01:45 and it is a great step forward for our scientific community,
01:49 to have a new drug available, therefore an antibody,
01:52 that will act against an interleukin, which is interleukin 5,
01:56 which is the factor that determines the growth, the development of osinophilia,
02:01 that is, those cells that can, we know, cause organ damage
02:04 and therefore induce a specific symptomatology.
02:07 This antibody is called mepolizumab,
02:10 it has the ability to modify and improve the symptoms, the signs
02:15 that these patients may present, and therefore,
02:18 improve the quality of life of these patients.
02:21 Often they are elderly patients, but also,
02:24 as frequently, young patients, whose quality of life
02:27 can be compromised by a consistent organ symptomatology,
02:31 and thanks to this therapeutic approach, great steps forward
02:34 have been made from this point of view.